Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) Gross Margin (2022 - 2025)

Historic Gross Margin for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Q3 2025 value amounting to 91.25%.

  • Arcutis Biotherapeutics' Gross Margin rose 35400.0% to 91.25% in Q3 2025 from the same period last year, while for Sep 2025 it was 89.96%, marking a year-over-year increase of 3900.0%. This contributed to the annual value of 90.27% for FY2024, which is 13700.0% down from last year.
  • Arcutis Biotherapeutics' Gross Margin amounted to 91.25% in Q3 2025, which was up 35400.0% from 90.81% recorded in Q2 2025.
  • Arcutis Biotherapeutics' Gross Margin's 5-year high stood at 96.06% during Q3 2023, with a 5-year trough of 62.9% in Q3 2022.
  • Over the past 4 years, Arcutis Biotherapeutics' median Gross Margin value was 87.7% (recorded in 2024), while the average stood at 85.52%.
  • Its Gross Margin has fluctuated over the past 5 years, first soared by 331600bps in 2023, then crashed by -83600bps in 2024.
  • Quarter analysis of 4 years shows Arcutis Biotherapeutics' Gross Margin stood at 83.62% in 2022, then dropped by 0bps to 83.39% in 2023, then rose by 8bps to 90.32% in 2024, then grew by 1bps to 91.25% in 2025.
  • Its Gross Margin stands at 91.25% for Q3 2025, versus 90.81% for Q2 2025 and 86.59% for Q1 2025.